Recent Updates
Recently added Catalysts

Mural Oncology plc

MURAFDA catalysts, PDUFA dates & pipeline intelligence
$2.04
▲ +0.01 · +0.49%

Last traded Dec 4, 2025. This price is not current.

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full MURA financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $0.9552W HIGH $4.74
Volume
127.78 K
Value Traded
259.92 K
Short % Float
2.77%
Days to Cover
1.4
0%Week
-2.4%1 Month
-1.93%3 Month
-22.52%6 Month
-87.84%5 Year
-87.84%All Time

Cash Data

Unlock MURA cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
35.21 M
EPS (TTM)
-6.93
P/E Ratio
-
Ent. Value
-21.83 M
Total Shares
17.33 M
Float Shares
15.62 M
Insiders
25.71%
Institutions
54.49%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every MURA catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

MURA Catalyst Timeline

Dated clinical, regulatory and corporate events for Mural Oncology plc

Unlock the full MURA catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How MURA actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-06-30nemvaleukin alfa (in combination with pembrolizumab) Phase 3 data readout Phase 3
Unlock 8 more MURA historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Showing 3 of 3 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Nemvaleukin alfa Monoclonal antibodyNCT04592653Advanced Solid TumorPhase 1/2 ACTIVE NOT_RECRUITING 78Dec 1, 2024
Nemvaleukin alfa Small moleculeCompletedNCT04144517Squamous Cell Carcinoma of Head and NeckPhase 2 COMPLETED 14Jan 7, 2022
ALKS 4230 Monoclonal antibodyCompletedNCT03861793Advanced Solid TumorsPhase 1/2 COMPLETED 359Mar 1, 2023
Unlock the MURA pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every MURA program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
nemvaleukin platinum-resistant ovarian cancerPhase 32025-03-25median overall survival nemvaleukin: 10.1 months; median overall survival chemotherapy: 9.8 months; hazard ratio: 0.98Read MoreMural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian CancerRead More
Scroll for more · summaries link to the source press release
Unlock every MURA trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock MURA insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Goodman Vicki LOfficer (Chief Medical Officer)Sell -5,036 84,727 held$2.08 11/10/2025
Unlock the full MURA insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in MURA

Fund % of Portfolio Current MV Shares Owned Activity
ORBIMED ADVISORS LLC 0 % 1.22 M 588.80 K
Unlock every fund holding MURA
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in MURA
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see MURA ownership
Insider and institutional ownership, quarter by quarter.

MURA Short Interest

Shares sold short, counted twice a month.

2.77%
Short % of Float
of tradable shares sold short
432.7K
Shares Sold Short
+3.6% vs prior count
1.4 Low
Days to Cover
trading days of normal volume to buy every short share back
302.5K
Avg Daily Volume
the average used for days to cover
Unlock MURA short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock MURA option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live MURA option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock MURA options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How MURA ranks across every disease it competes in

Competitive Position is a premium feature
See how MURA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

MURA News

About Mural Oncology plc

BIOPHARMAWATCH ELITE PLUS
Trade the next MURA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime